ASSEMBLY BIOSCIENCES, INC.
ASMBDrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
ASMB Earnings Report
EPS Est: $-0.70 | FQ end 2026-06
How ASMB's past catalysts played out
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ASSEMBLY BIOSCIENCES, INC.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in ASSEMBLY BIOSCIENCES, INC.'s (ASMB) pipeline across Phase 2. Its lead program is SOC ETV (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ASSEMBLY BIOSCIENCES, INC.'s next FDA catalyst?→
ASSEMBLY BIOSCIENCES, INC.'s (ASMB) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ASMB biotech catalysts?→
Add ASMB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ASSEMBLY BIOSCIENCES, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.